Pharmaceutical returns are often treated as a routine task. Products expire, recalls happen and inventory is cleared out as needed. But recent data shows that unsaleable returns are more than an operational chore. They offer insight into financial performance, compliance risk and how well pharmacy operations are keeping up with a changing supply chain.
Data from Inmar, shared as part of the 96th edition of the HDA Factbook released in November 2025 and discussed during a recent industry webinar, highlights several important trends in unsaleable pharmaceutical returns. While the total volume of unsaleable drugs is declining, the value tied to those returns remains significant—and increasingly complex to manage.
Understanding what is changing, and why, can help pharmacies take a more informed and proactive approach to returns.
What Are Unsaleable Pharmaceutical Returns?
Unsaleable pharmaceutical returns include drugs that can no longer be sold or dispensed. This category covers expired medications, recalled products, damaged goods and items that do not meet manufacturer or regulatory requirements.
While many pharmacies view these products as unavoidable losses, returns are not always a dead end. When handled correctly and within policy guidelines, many unsaleable products are eligible for manufacturer credit. Capturing that value depends on timing, documentation and adherence to increasingly detailed return policies.
Unsaleable Volume Is Down, but Financial Impact Remains
One of the most notable trends in the latest data is that the percentage of pharmaceuticals deemed unsaleable has declined year over year. In 2024, unsaleable products represented about 2.9 percent of total pharmaceutical volume in the U.S., down from just over 3.1 percent the year before.
At first glance, this might suggest that returns are becoming less important. The data tells a different story.
Even as unsaleable volume has decreased, the average percentage of returns eligible for credit has increased. In 2024, nearly 80 percent of returns, measured in dollars, were creditable—up from about 76.5 percent the year before. This means more value is potentially recoverable, but only if returns are managed correctly.
The implication is clear: fewer returns do not necessarily mean less financial exposure. In fact, as creditable value increases, the cost of missed credits grows as well.
Returns Vary Widely by Pharmacy Type
Another key finding from the data is that unsaleable returns do not affect all pharmacies equally.
On average, a hospital pharmacy handles more than twice the dollar value of unsaleable returns compared with a retail pharmacy. In 2024, the average hospital pharmacy saw more than $213,000 in unsaleable returns, while the average retail pharmacy saw just under $95,000.
These differences reflect variations in inventory size, drug mix and operational complexity. They also help explain why returns management can feel manageable in one setting and overwhelming in another.
Regardless of setting, however, the underlying challenge is the same: higher-value returns increase the stakes for accuracy, speed and compliance.
Branded Drugs Continue to Drive Higher Return Rates
The data also shows a consistent difference between branded and generic products.
Branded drugs continue to have higher return rates than generics, even though both categories saw declines year over year. In 2024, branded products had an unsaleable return rate of about 5.9 percent, compared with roughly 2.4 percent for generics.
Because branded drugs often carry higher price tags, even small inefficiencies in how they are returned can result in meaningful financial losses. This makes visibility and precision especially important when managing branded inventory nearing expiration or subject to recall.
Why Fewer Returns Do Not Mean Less Work
While declining unsaleable volume may sound like good news, it does not necessarily translate into simpler returns processes.
In many cases, fewer returns mean that each return matters more. As the average creditable value increases, so does the need for accurate identification, proper documentation and timely submission. Errors that once had limited financial impact can now result in larger losses.
At the same time, returns are becoming harder to manage due to changes in manufacturer policies, expiration windows and data requirements—factors explored in more detail later in this blog series.
Returns as a Window Into Operational Health
Pharmaceutical returns reflect more than inventory cleanup. They reveal how well a pharmacy is managing expiration risk, responding to recalls and aligning internal processes with external requirements.
For example:
- Delayed returns can push products outside credit eligibility windows.
- Incomplete documentation can result in denied credits.
- Manual or fragmented workflows increase the risk of error and non-compliance.
Taken together, these issues make returns a useful lens for assessing operational efficiency and financial discipline.
A Shift From Back-Office Task to Strategic Process
Historically, returns have been treated as a back-office function—necessary, but not strategic. The latest data suggests that mindset is changing.
As returns grow more data-driven and policy-driven, they are becoming closely tied to broader goals such as margin protection, compliance confidence and patient safety. Pharmacies that view returns as part of a larger operational system are better positioned to adapt as requirements evolve.
This shift does not require radical change overnight. It starts with understanding the trends, recognizing where value is at risk and using data to guide better decisions.
Returns as a Strategic Signal
The latest data on unsaleable pharmaceutical returns shows a clear shift. While fewer products are being returned overall, the value tied to those returns is increasing. At the same time, policies, data requirements and operational expectations are becoming more complex.
For pharmacies, this means returns deserve more attention than they have traditionally received. When managed well, the returns process can support stronger financial performance, reduce compliance risk and improve visibility across inventory and operations. When managed poorly, it can quietly erode margins and create unnecessary exposure.
Viewing returns as a strategic signal—rather than a routine task—helps pharmacies better understand where value is being lost, where processes are breaking down and where improvements can make the greatest impact. As the pharmaceutical supply chain continues to evolve, that insight will become increasingly important.
Optimize your pharmacy returns process